NCT00692146View on ClinicalTrials.gov

Study to Investigate the Effects Single Oral Dose of AZD1386 (Capsaicin)

PHASE1CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions

Capsaicin Evoked PainHeat Sensitivity

Interventions

DRUG

AZD1386

Oral solution fixed dose (95 mg given orally on two occasions)

DRUG

Placebo

Oral solution fixed dose (95 mg given orally on two occasions)

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY